Phase 2a Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

VDA-1102 led to an objective response rate of 56% in patients with mycosis fungoides, according to findings from an interim analysis of a phase 2a study.

Eteläuomen läiMax herzbergVidac pharmaEmmilia hodakMinistry of healthRabin center beilinson hospitalHelsinki committeeRabin centerBeilinson hospitalVda 1102Small moleculeMycosis fungoidesCutaneoust cell lymphomaPhase 2a study